A one-fifth dose of Bavarian Nordic’s mpox vaccine Jynneos can elicit a similar antibody response as its standard-dose regimen, according to findings presented Saturday at the European Society of ...
Going forward, we will focus on key business areas that implement a simplified organization to improve our cost structure and ...
RECCE® 327 is not a preventive vaccine and is not approved for use in humans in any country. The investigational recurrent UTI vaccine MV140 is available in Australia and various countries in 2024.
In February 2024, the Committee for Medicinal Products for Human Use (CHMP) under EMA granted accelerated assessment for the MAA for the CHIKV VLP vaccine candidate, which Bavarian Nordic plans to ...
In February 2024, the Committee for Medicinal Products for Human Use (CHMP) under EMA granted accelerated assessment for the MAA for the CHIKV VLP vaccine candidate, which Bavarian Nordic plans to ...
In February 2024, the Committee for Medicinal Products for Human Use (CHMP) under EMA granted accelerated assessment for the MAA for the CHIKV VLP vaccine candidate, which Bavarian Nordic plans to ...
Bavarian Nordic will submit additional data over the coming months, aiming to complete the BLA submission before the end of the first half of 2024 to support a potential FDA approval of the vaccine in ...
COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract valued at EUR 65 million to supply its MVA-BN ® smallpox vaccine to the strategic ...
In February 2024, the Committee for Medicinal Products for Human Use (CHMP) under EMA granted accelerated assessment for the MAA for the CHIKV VLP vaccine candidate, which Bavarian Nordic plans to ...
COPENHAGEN, Denmark, April 29, 2024 - Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract valued at EUR 65 million to supply its MVA-BN ® smallpox vaccine to the strategic ...
COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract valued at EUR 65 million to supply its MVA-BN ® smallpox vaccine to the strategic reserve ...